Abstract
Purpose
This article reviews the current evidence surrounding pancreatic cancer screening. The current targets of screening include identification of early pancreatic cancer, as well as the two most important precursor lesions; intraductal papillary mucinous neoplasm and high grade pancreatic intraepithelial neoplasia. Given the relatively low incidence of pancreatic adenocarcinoma in the general population, patients with elevated risk based on family history or an underlying genetic syndrome are felt to be the most appropriate patients to undergo screening.
Methods
An extensive review of the literature was performed and the major findings of the available literature regarding pancreatic screening are reviewed in detail.
Results
Several prospective trials have evaluated pancreatic cancer screening in high-risk groups. The results of those trials are summarized in this article. Current consensus guidelines and recommendations from the International Cancer of the Pancreas Screening Consortium Summit are also discussed.
Conclusions
The exact benefit of pancreatic cancer screening remains unclear at this time, but emerging evidence suggests that there is a window of opportunity to detect precursor lesions and early pancreatic adenocarcinomas in high-risk patient populations. Better understanding of the pathway of carcinogenesis will hopefully improve our ability to detect early, resectable pancreatic carcinomas, and provide a mortality benefit to patients at significantly elevated risk of pancreatic adenocarcinoma.
Similar content being viewed by others
References
National Cancer Institute Surveillance, Epidemiology, and End Results Program Cancer Statistics (2014). National Cancer Institute. https://seer.cancer.gov/statfacts/html/pancreas.html. Accessed July 1, 2017.
Wada K, Takaori K, Traverso LW (2015) Screening for pancreatic cancer. Surg Clin North Am 95(5):1041–1052. doi:10.1016/j.suc.2015.05.010
Poruk KE, Firpo MA, Mulvihill SJ (2014) Screening for pancreatic cancer. Adv Surg 48:115–136
Canto MI, Hruban RH, Fishman EK et al. (2012) Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 142(4): 796–804; quiz e14–15. doi:10.1053/j.gastro.2012.01.005
Poruk KE, Firpo MA, Adler DG, Mulvihill SJ (2013) Screening for pancreatic cancer: why, how, and who? Ann Surg 257(1):17–26. doi:10.1097/SLA.0b013e31825ffbfb
Schneider R, Slater EP, Sina M, et al. (2011) German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. Fam Cancer 10(2):323–330. doi:10.1007/s10689-010-9414-x
Helmstaedter L, Riemann JF (2007) Endoscopic ultrasound and early diagnosis of pancreatic cancer. Am J Surg 194:S87–S90. doi:10.1016/j.amjsurg.2007.05.009
Grover S, Jajoo K (2016) Screening for pancreatic cancer in high-risk populations. Gastroenterol Clin North Am. 45(1):117–127. doi:10.1016/j.gtc.2015.10.001
Chang MC, Wong JM, Chang YT (2014) Screening and early detection of pancreatic cancer in high risk population. World J Gastroenterol 20(9):2358–2364. doi:10.3748/wjg.v20.i9.2358
Langer P, Kann PH, Fendrich V, et al. (2009) Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 58(10):1410–1418. doi:10.1136/gut.2008.171611
Bhutani MS, Verma D, Guha S, et al. (2009) Is endoscopic ultrasound “sound” for pancreatic cancer screening? J Clin Gastroenterol 43(9):797–802. doi:10.1097/MCG.0b013e3181b3ab58
Canto MI, Harinck F, Hruban RH, et al. (2013) International Cancer of the Pancreatic Screening (CAPS) consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 62(3):339–347
Okano K, Suzuki Y (2014) Strategies for early detection of resectable pancreatic cancer. World J Gastroenterol 20(32):11230–11240
Lahat G, Ben Haim M, Nachmany I, et al. (2009) Pancreatic incidentalomas: high rate of potentially malignant tumors. J Am Coll Surg 209(3):313–319
Tsuchiya R, Noda T, Harada N, et al. (1986) Collective review of small carcinomas of the pancreas. Ann Surg 203(1):77–81
Winter JM, Cameron JL, Lillemoe KD, et al. (2006) Periampullary and pancreatic incidentaloma: a single institution’s experience with an increasingly common diagnosis. Ann Surg 243(5):673–680
Canto MI, Goggins M, Hruban RH, et al. (2006) Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 4(6):766–781
Zubarik R, Gordon SR, Lidofsky SD, et al. (2011) Screening for pancreatic cancer in a high-risk population with serum CA 19-9 and targeted EUS: a feasibility study. Gastrointest Endosc 74(1):87–95. doi:10.1016/j.gie.2011.03.1235
Al-Sukhni W, Borgida A, Rothenmund H, et al. (2012) Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. J Gastrointest Surg 16(4):771–783. doi:10.1007/s11605-011-1781-6
Ariyama J, Suyama M, Ogawa K, et al. (1990) The detection and prognosis of small pancreatic carcinoma. Int J Pancreatol 7(1–3):37–47
Becker AE, Hernandez YG, Frucht H, Lucas AL (2014) Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection. World J Gastroenterol 20(32):11182–11198. doi:10.3748/wjg.v20.i32.11182
Lu C, Xu CF, Wan XY, et al. (2015) Screening for pancreatic cancer in familial high-risk individuals: a systematic review. World J Gastroenterol 21(28):8678–8686. doi:10.3748/wjg.v21.i28.8678
Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB (1999) Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 131(4):247–255
Verna EC, Hwang C, Stevens PD, et al. (2010) Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res 16(20):5028–5037. doi:10.1158/1078-0432.CCR-09-3209
Poley JW, Kluijt I, Gouma DJ, et al. (2009) The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 104(9):2175–2181. doi:10.1038/ajg.2009.276
Ludwig E, Olson SH, Bayuga S, et al. (2011) Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol 106(5):946–954. doi:10.1038/ajg.2011.65
Harinck F, Konings IC, Kluijt I, et al. (2016) A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals. Gut 65(9):1505–1513. doi:10.1136/gutjnl-2014-308008
Shi C, Klein AP, Goggins M, et al. (2009) Increased prevalence of precursor lesions in familial pancreatic cancer patients. Clin Cancer Res 15(24):7737–7743
Del Chiaro M, Verbeke CS, Kartalis N, et al. (2015) Short-term results of a magnetic resonance imaging-based swedish screening program for Individuals at Risk for Pancreatic Cancer. JAMA Surg 150(6):512–518. doi:10.1001/jamasurg.2014.3852
Del Chiaro M, Segersvärd R, Lohr M, Verbeke C (2014) Early detection and prevention of pancreatic cancer: is it really possible today? World J Gastroenterol 20(34):12118–12131. doi:10.3748/wjg.v20.i34.12118
Nagata N, Kawazoe A, Mishima S, et al. (2016) Development of pancreatic cancer, disease-specific mortality, and all-cause mortality in patients with nonresected IPMNs: a long-term cohort study. Radiology 278(1):125–134. doi:10.1148/radiol.2015150131
Tanno S, Nakano Y, Nishikawa T, et al. (2008) Natural history of branch duct intraductal papillary-mucinous neoplasms of the pancreas without mural nodules: long-term follow-up results. Gut 57(3):339–343
Izawa T, Obara T, Tanno S, et al. (2001) Clonality and field cancerization in intraductal papillary-mucinous tumors of the pancreas. Cancer 92(7):1807–1817
Vasen HF, Wasser M, van Mil A, et al. (2011) Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology 140(3):850–856. doi:10.1053/j.gastro.2010.11.048
Maitra A, Kern SE, Hruban RH (2006) Molecular pathogenesis of pancreatic cancer. Best Pract Res Clin Gastroenterol 20(2):211–226
Yachida S, Jones S, Bozic I, et al. (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467(7319):1114–1117. doi:10.1038/nature09515
Yu J, Blackford AL, Dal Molin M, Wolfgang CL, Goggins M (2015) Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. Gut 64(11):1783–1789. doi:10.1136/gutjnl-2014-308653
Gangi S, Fletcher JG, Nathan MA, et al. (2004) Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer: retrospective review of CT scans obtained before diagnosis. AJR Am J Roentgenol 182(4):897–903
Furukawa H, Okada S, Saisho H, et al. (1996) Clinicopathologic features of small pancreatic adenocarcinoma. A collective study. Cancer 78(5):986–990
Hruban RH, Canto MI, Goggins M, Schulick R, Klein AP (2010) Update on familial pancreatic cancer. Adv Surg 44:293–311
Canto MI, Goggins M, Yeo CJ, et al. (2004) Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2(7):606–621
Klein AP, Brune KA, Petersen GM, et al. (2004) Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 64(7):2634–2638
Tersmette AC, Petersen GM, Offerhaus GJ, et al. (2001) Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 7(3):738–744
Kimmey MB, Bronner MP, Byrd DR, Brentnall TA (2002) Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc 56(4 Suppl):S82–S86
Giardiello FM, Brensinger JD, Tersmette AC, et al. (2000) Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119(6):1447–1453
van Lier MG, Wagner A, Mathus-Vliegen EM, et al. (2010) High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol 105(6):1258–1264; author reply 1265. doi:10.1038/ajg.2009.725
Borg A, Sandberg T, Nilsson K, et al. (2000) High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 92(15):1260–1266
Vasen HF, Gruis NA, Frants RR, et al. (2000) Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 87(6):809–811
Naderi A, Couch FJ (2002) BRCA2 and pancreatic cancer. Int J Gastrointest Cancer 31(1–3):99–106
Win AK, Lindor NM, Winship I, et al. (2013) Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst 105(4):274–279. doi:10.1093/jnci/djs525
Geary J, Sasieni P, Houlston R, et al. (2008) Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer 7(2):163–172
Howes N, Lerch MM, Greenhalf W, et al. (2004) Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol 2(3):252–261
Rebours V, Boutron-Ruault MC, Schnee M, et al. (2008) Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. Am J Gastroenterol 103(1):111–119. doi:10.1111/j.1572-0241.2007.01597.x
Giardiello FM, Offerhaus GJ, Lee DH, et al. (1993) Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 34(10):1394–1396
Bartsch DK, Slater EP, Carrato A, et al. (2016) Refinement of screening for familial pancreatic cancer. Gut 65(8):1314–1321. doi:10.1136/gutjnl-2015-311098
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This study received no funding.
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Lindquist, C.M., Miller, F.H., Hammond, N.A. et al. Pancreatic cancer screening. Abdom Radiol 43, 264–272 (2018). https://doi.org/10.1007/s00261-017-1308-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00261-017-1308-z